Filing search / Context Therapeutics Inc. / "Innovation"

424B3

CNTX Context Therapeutics Inc.

12 Apr 22

Prospectus supplement

4:14pm

and Innovation Act was enacted as part of the Affordable Care Act to establish an abbreviated pathway for the approval of biosimilar and interchangeable … and Innovation Act, an application for a biosimilar product cannot be approved by the FDA until 12 years after the reference product was approved under a BLA

POS AM

CNTX Context Therapeutics Inc.

4 Apr 22

Prospectus update (post-effective amendment)

5:08pm

Competition and Innovation Act was enacted as part of the Affordable Care Act to establish an abbreviated pathway for the approval of biosimilar … and Innovation Act, an application for a biosimilar product cannot be approved by the FDA until 12 years after the reference product was approved under

424B3

CNTX Context Therapeutics Inc.

23 Mar 22

Prospectus supplement

4:27pm

on the “Women’s Health: Progress and Innovation Continue to Drive Increased Investor Interest” panel at Biotech Showcase™ 2022. In December 2021, announced

10-K

kwxd swtwdpjni766

23 Mar 22

Annual report

4:17pm

8-K

EX-99.1

16zly0wq2n91dm

23 Mar 22

Context Therapeutics® Reports Full Year 2021 Operating and Financial Results

4:06pm

424B4

i6ea9u7on lyc6o5zh

17 Dec 21

Prospectus supplement with pricing info

8:00am

424B4

22n0p s1c

20 Oct 21

Prospectus supplement with pricing info

5:05pm

S-1

8m6kzl

27 May 21

IPO registration

5:28pm

DRS/A

rzzzgc5gx6z0v

3 May 21

Draft registration statement (amended)

12:00am

DRS

52kmhv3ku8n

22 Mar 21

Draft registration statement

12:00am